Showing 3081-3090 of 5621 results for "".
- Prevent Blindness Declares July as Dry Eye Awareness Monthhttps://modernod.com/news/prevent-blindness-declares-july-as-dry-eye-awareness-month/2479328/Nearly 16 million Americans have dry eye, according to the
- Two Shots of Pfizer, AstraZeneca COVID-19 Vaccines Effective Against Delta Variant: Studyhttps://modernod.com/news/two-shots-of-pfizer-astrazeneca-covid-19-vaccines-effective-against-delta-variant-study/2479295/A real world study conducted by Public Health England shows tha
- Notal Vision Raises Up to $60 Million to Support Development of its Home OCT Technologyhttps://modernod.com/news/notal-vision-raises-up-to-60-million-to-support-development-of-its-home-oct-technology/2479251/Notal Vision announced the closing of a Series D financing to support the commercial growth of the company’s current service, the ForeseeHome AMD Monitoring Program, as well as the go-to-market strategy for its Home OCT pipeline technology. The financing was co-led by Soleus Capital and the compa
- Vyluma Launches With Myopia Treatment In Phase 3 Developmenthttps://modernod.com/news/vyluma-inc-launches-with-robust-opthalmic-portfolio-leading-with-a-pharmaceutical-treatment-in-phase-iii-for-myopia/2479239/Vyluma announced its establishment as a wholly-owned subsidiary of Nevakar Inc., focusing on pharmaceutical ophthalmic solutions. The pipeline of novel therapies is led by NVK002, a pharmaceutical atropine eye drop to slow the progression of myopia in children. NVK002 is currently in late phase 3
- Rayner Receives FDA Approval for RayOne Spheric Monofocal IOLhttps://modernod.com/news/rayner-receives-fda-approval-for-rayone-spheric-monofocal-iol/2479221/Rayner has received FDA approval for the RayOne Spheric fully-preloaded monofocal IOL. The approval marks Rayner’s third FDA approval in under 3 years within its RayOne preloaded IOL portfolio. RayOne Spheric joins RayOne Aspheric (FDA approved December 2018) and RayOne EMV, a new non-diffractive
- SIFI and Bausch Health Russia Announce Strategic Commercial Partnershiphttps://modernod.com/news/sifi-and-bausch-health-russia-announce-strategic-commercial-partnership/2479213/Italian ophthalmic company SIFI announced it has entered into a strategic multi-year agreement with Bausch Health Russia to market its products treating ophthalmic disorders in Russia. Terms of the deal were not disclosed. Initial sales are expected in 2021, marketing 5 SIFI product
- Lineage Cell: OpRegen Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With GAhttps://modernod.com/news/lineage-cell-opregen-clinical-data-continues-to-demonstrate-improvements-in-patients-with-dry-amd-with-ga/2479160/Lineage Cell Therapeutics announced that updated interim results from its ongoing, 24-patient phase 1/2a clinical study of its lead product candidate, OpRegen, were reported at the 2021 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2021). OpRegen is an investigational
- Mount Sinai Ophthalmologists use Breakthrough Imaging to Understand Eye Damage from Rare Congenital Retinal Diseasehttps://modernod.com/news/mount-sinai-ophthalmologists-use-breakthrough-imaging-to-understand-eye-damage-from-rare-congenital-retinal-disease/2479098/Researchers from New York Eye and Ear Infirmary of Mount Sinai used adaptive optics–retinal imaging technology that allows clinicians to examine microscopic structures of the eye in living patients with extreme detail in real time–to analyze and better understand a rare retinal disease called “fu
- Nova Eye: 24-Month iTrack Data Demonstrate Real-World Efficacy of Canaloplasty as Both a Standalone and Combined MIGS Procedurehttps://modernod.com/news/nova-eye-24-month-itrack-data-demonstrate-real-world-efficacy-of-canaloplasty-as-both-a-standalone-and-combined-migs-procedure/2479091/Nova Eye Medical is reporting the peer-reviewed publication of 24-month data for its proprietary iTrack minimally invasive glaucoma surgery (MIGS) technology. Published in Clinical Oph
- Essilor to Present New Results for its Stellest Lens for Children With Myopiahttps://modernod.com/news/essilor-to-present-new-results-for-its-stellest-lens-for-children-with-myopia/2479062/Essilor will unveil pivotal 2-year clinical trial results of its Stellest lens for myopia. The 2-year results demonstrate that Essilor Stellest lenses slow down myopia progression by 67% on average, when compared to single vision lenses, when worn at least 12 hours a day,1 according to